Study details
Enrolling now
Pioglitazone Trial for Kidney Disease
The University of Texas at Arlington
NCT IDNCT03471117ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
28
Study length
about 8 years
Ages
35–70
Locations
2 sites in TX
About this study
This trial is testing whether a short-term treatment with pioglitazone can reduce sympathetic nerve activity in people with chronic kidney disease. The goal is to see if pioglitazone helps lower the risk of cardiovascular problems and death in these patients.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Pioglitazone
PhasePhase 4
DrugPioglitazone
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
pioglitazone (Thiazolidinedione; improves insulin sensitivity by activating PPAR-gamma)
Drug routes
oral (Oral Tablet)
Body systems
Renal